↓ Skip to main content

Dove Medical Press

Article Metrics

Potential role of odanacatib in the treatment of osteoporosis

Overview of attention for article published in Clinical Interventions in Aging, July 2012
Altmetric Badge

Mentioned by

2 Facebook pages


27 Dimensions

Readers on

39 Mendeley
Potential role of odanacatib in the treatment of osteoporosis
Published in
Clinical Interventions in Aging, July 2012
DOI 10.2147/cia.s26729
Pubmed ID

Kong Wah Ng, Ng KW


Cathepsin K is a key enzyme involved in the degradation of organic bone matrix by osteoclasts. Inhibition of bone resorption observed in human and animal models deficient for cathepsin K has identified this enzyme as a suitable target for intervention by small molecules with the potential to be used as therapeutic agents in the treatment of osteoporosis. Odanacatib (ODN) is a nonbasic selective cathepsin K inhibitor with good pharmacokinetic parameters such as minimal in vitro metabolism, long half-life, and oral bioavailability. In preclinical studies, ovariectomized monkeys and rabbits treated with ODN showed substantial inhibition of bone resorption markers along with increases in bone mineral density (BMD). Significant differences were observed in the effects of ODN treatment compared with those of other antiresorptive agents such as bisphosphonates and denosumab. ODN displayed compartment-specific effects on trabecular versus cortical bone formation, with treatment resulting in marked increases in periosteal bone formation and cortical thickness in ovariectomized monkeys whereas trabecular bone formation was reduced. Furthermore, osteoclasts remained viable. Phase I and II studies conducted in postmenopausal women showed ODN to be safe and well tolerated. After 5 years, women who received ODN 50 mg weekly continuously from year 1 (n = 13), showed BMD increases from baseline of 11.9% at the lumbar spine, 9.8% at the femoral neck, 10.9% at the hip trochanter, and 8.5% at the total hip. Additionally, these subjects maintained a low level of the urine bone resorption marker N-terminal telopeptide/creatinine (-67.4% from baseline) through 5 years of treatment, while levels of serum bone-specific alkaline phosphatase remained only slightly reduced relative to baseline (-15.3%). In women who were switched from ODN to placebo after 2 years, bone turnover markers were transiently increased and BMD gains reversed after 12 months off medication. Adverse experiences in the ODN-treated group were not significantly different from the placebo group. In conclusion, available data suggests that cathepsin K inhibition could be a promising intervention with which to treat osteoporosis. Ongoing studies are expected to provide information on the long-term efficacy in fracture reduction and safety of prolonged treatment with ODN.

Mendeley readers

The data shown below were compiled from readership statistics for 39 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 3%
Unknown 38 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 8 21%
Student > Master 7 18%
Student > Ph. D. Student 6 15%
Student > Bachelor 5 13%
Professor > Associate Professor 2 5%
Other 7 18%
Unknown 4 10%
Readers by discipline Count As %
Medicine and Dentistry 17 44%
Agricultural and Biological Sciences 6 15%
Pharmacology, Toxicology and Pharmaceutical Science 5 13%
Biochemistry, Genetics and Molecular Biology 3 8%
Business, Management and Accounting 1 3%
Other 1 3%
Unknown 6 15%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 July 2015.
All research outputs
of 5,313,619 outputs
Outputs from Clinical Interventions in Aging
of 761 outputs
Outputs of similar age
of 184,159 outputs
Outputs of similar age from Clinical Interventions in Aging
of 21 outputs
Altmetric has tracked 5,313,619 research outputs across all sources so far. This one is in the 16th percentile – i.e., 16% of other outputs scored the same or lower than it.
So far Altmetric has tracked 761 research outputs from this source. They receive a mean Attention Score of 3.9. This one is in the 9th percentile – i.e., 9% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 184,159 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 20th percentile – i.e., 20% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 21 others from the same source and published within six weeks on either side of this one. This one is in the 14th percentile – i.e., 14% of its contemporaries scored the same or lower than it.